Table 3. Network meta-analysis results for long-term and short-term prognoses.

	3 years OS
5 years OS	Control	1.16 (0.79, 1.70)	0.70 (0.55, 0.90)	0.64 (0.52, 0.80)	0.80 (0.65, 0.99)	0.68 (0.17, 2.70)	0.72 (0.56, 0.91)
	1.13 (0.79, 1.60)	A	0.61 (0.39, 0.95)	0.56 (0.36, 0.86)	0.69 (0.45, 1.07)	0.59 (0.14, 2.45)	0.62 (0.40, 0.96)
	0.70 (0.59, 0.85)	0.62 (0.42, 0.93)	C	0.92 (0.70, 1.20)	1.14 (0.84, 1.55)	0.97 (0.24, 3.88)	1.02 (0.77, 1.34)
	0.64 (0.52, 0.79)	0.57 (0.39, 0.83)	0.91 (0.70, 1.18)	C+A	1.24 (0.95, 1.63)	1.06 (0.27, 4.12)	1.11 (0.95, 1.31)
	0.80 (0.65, 0.98)	0.71 (0.47, 1.06)	1.13 (0.88, 1.45)	1.25 (0.93, 1.67)	N	0.85 (0.21, 3.41)	0.89 (0.68, 1.17)
	0.54 (0.31, 0.93)	0.48 (0.25, 0.90)	0.77 (0.44, 1.35)	0.84 (0.51, 1.39)	0.68 (0.38, 1.21)	N+A	1.05 (0.27, 4.15)
	0.74 (0.57, 0.96)	0.65 (0.42, 1.01)	1.05 (0.82, 1.33)	1.15 (0.83, 1.60)	0.92 (0.71, 1.20)	1.36 (0.75, 2.48)	N+C
	CR
1 year OS	Control	1.73 (0.82, 3.78)	3.06 (2.25, 4.28)	2.46 (1.16, 6.40)	2.89 (1.09, 8.98)	-	4.35 (1.89, 11.86)
	1.12 (0.57, 2.18)	A	1.76 (0.77, 3.97)	1.41 (0.50, 4.86)	1.68 (0.47, 6.66)	-	2.51 (0.83, 8.63)
	0.40 (0.21, 0.73)	0.35 (0.14, 0.88)	C	0.81 (0.36, 2.04)	0.95 (0.34, 3.01)	-	1.43 (0.64, 3.52)
	0.46 (0.28, 0.76)	0.42 (0.18, 0.95)	1.17 (0.59, 2.34)	C+A	1.20 (0.30, 4.28)	-	1.79 (0.52, 5.70)
	0.91 (0.60, 1.37)	0.81 (0.37, 1.78)	2.29 (1.11, 4.72)	1.95 (1.04, 3.65)	N	-	1.51 (0.36, 6.03)
	-	-	-	-	-	N+A
	0.40 (0.20, 0.80)	0.36 (0.14, 0.93)	1.01 (0.48, 2.11)	0.86 (0.45, 1.66)	0.44 (0.21, 0.94)	-	N+C

Abbreviation: A, Adjuvant chemotherapy; C, Concurrent chemotherapy; N, Neoadjuvant chemotherapy

5 years overall survival, 3 years overall survival, 1 year overall survival, represented by hazard ratio (HR) and 95% credible interval (CrI), and complete response represented by odds ratio (OR) and 95% credible interval (CrI). In lower half of the table, row treatments are compared against column treatments, whereas in the upper half, column treatments are compared against row treatments.